These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2997764)

  • 21. The minimum effective dose of estrogen for prevention of postmenopausal bone loss.
    Lindsay R; Hart DM; Clark DM
    Obstet Gynecol; 1984 Jun; 63(6):759-63. PubMed ID: 6374537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis.
    Riggs BL; Wahner HW; Dunn WL; Mazess RB; Offord KP; Melton LJ
    J Clin Invest; 1981 Feb; 67(2):328-35. PubMed ID: 7462421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function.
    Nielsen HE; Rømer FK; Melsen F; Christensen MS; Hansen HE
    Clin Nephrol; 1980 Mar; 13(3):103-8. PubMed ID: 7379358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study.
    Riis B; Thomsen K; Christiansen C
    N Engl J Med; 1987 Jan; 316(4):173-7. PubMed ID: 3540668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study.
    Pacifici R; McMurtry C; Vered I; Rupich R; Avioli LV
    J Clin Endocrinol Metab; 1988 Apr; 66(4):747-53. PubMed ID: 3126214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series.
    Amerling R; Harbord NB; Pullman J; Feinfeld DA
    Blood Purif; 2010; 29(3):293-9. PubMed ID: 20090316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure.
    Compston JE
    Bone; 2007 Jun; 40(6):1447-52. PubMed ID: 17045858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microcrystalline calcium hydroxyapatite compound in corticosteroid-treated rheumatoid patients: a controlled study.
    Nilsen KH; Jayson MI; Dixon AS
    Br Med J; 1978 Oct; 2(6145):1124. PubMed ID: 709260
    [No Abstract]   [Full Text] [Related]  

  • 29. Detection of prefracture spinal osteoporosis using bone mineral absorptiometry.
    Ross PD; Wasnich RD; Vogel JM
    J Bone Miner Res; 1988 Feb; 3(1):1-11. PubMed ID: 3213600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone mineral alterations and Mg content in aging.
    Mongiorgi R; Gnudi S; Moroni A; Bertocchi G; Galliani I; Benfenati L
    Boll Soc Ital Biol Sper; 1990 Jul; 66(7):623-30. PubMed ID: 1964563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of chronic prednisolone treatment on bone resorption and bone composition in intact and ovariectomized rats and in ovariectomized rats receiving beta-estradiol.
    Goulding A; Gold E
    Endocrinology; 1988 Feb; 122(2):482-7. PubMed ID: 3338411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of strontium ranelate administration on bisphosphonate-altered hydroxyapatite: Matrix incorporation of strontium is accompanied by changes in mineralization and microstructure.
    Busse B; Jobke B; Hahn M; Priemel M; Niecke M; Seitz S; Zustin J; Semler J; Amling M
    Acta Biomater; 2010 Dec; 6(12):4513-21. PubMed ID: 20654744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diphosphonates inhibit bone resorption by macrophages in vitro.
    Chambers TJ
    J Pathol; 1980 Nov; 132(3):255-62. PubMed ID: 7431161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of nandrolone therapy on forearm bone mineral content in osteoporosis.
    Need AG; Horowitz M; Morris HA; Walker CJ; Nordin BE
    Clin Orthop Relat Res; 1987 Dec; (225):273-8. PubMed ID: 3677513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis.
    Kirk AP; Jain S; Pocock S; Thomas HC; Sherlock S
    Gut; 1980 Jan; 21(1):78-83. PubMed ID: 6988304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantification of bone density and mineral content.
    Bentley HB
    Radiogr Today; 1989 Jan; 55(620):16-8. PubMed ID: 2590411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in bone histomorphometry and bone mineral during treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium.
    Lindholm TS; Nilsson OS; Elmstedt E; Eriksson SA; Lindholm TC; Kyhle BR
    Acta Vitaminol Enzymol; 1981; 3(3):170-6. PubMed ID: 7347489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Irreversible bone loss in osteomalacia. Comparison of radial photon absorptiometry with iliac bone histomorphometry during treatment.
    Parfitt AM; Rao DS; Stanciu J; Villanueva AR; Kleerekoper M; Frame B
    J Clin Invest; 1985 Dec; 76(6):2403-12. PubMed ID: 4077986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Skeletal changes in aging and disease.
    Arnold JS; Bartley MH; Tont SA; Jenkins DP
    Clin Orthop Relat Res; 1966; 49():17-38. PubMed ID: 5962617
    [No Abstract]   [Full Text] [Related]  

  • 40. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial.
    Reeve J; Meunier PJ; Parsons JA; Bernat M; Bijvoet OL; Courpron P; Edouard C; Klenerman L; Neer RM; Renier JC; Slovik D; Vismans FJ; Potts JT
    Br Med J; 1980 Jun; 280(6228):1340-4. PubMed ID: 6992932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.